Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest announcement is out from Cryosite Limited ( (AU:CTE) ).
Cryosite Limited reported a 4% increase in revenue from ordinary activities for the half-year ending December 31, 2024, compared to the previous year. Despite a slight 1% decrease in after-tax profit, the company experienced a 19% rise in EBIT and a 15% increase in EBITDA, highlighting improved trading conditions. Additionally, a 33% increase in unfranked dividends was noted, reflecting a stronger financial position. The company’s net tangible assets per ordinary security fell due to a share reduction, and it reported no bank borrowings, suggesting a stable financial outlook.
More about Cryosite Limited
Cryosite Limited operates within the biotechnology sector, providing specialized services related to the storage and management of biological materials. The company focuses on offering cryogenic storage solutions, catering to the healthcare and life sciences industries.
YTD Price Performance: -8.24%
Average Trading Volume: 2,750
Technical Sentiment Consensus Rating: Sell
Current Market Cap: A$38.07M
For detailed information about CTE stock, go to TipRanks’ Stock Analysis page.
